SCHEMBL812482

SCHEMBL812482

CCCCCCOS(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.50
GLA P06280 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
EPHX2 P34913 1/20 0.50
MCHR1 Q99705 1/20 0.50
BLM P54132 1/20 0.50
CA1 P00915 10/20 0.47
CA2 P00918 10/20 0.47
CA9 Q16790 9/20 0.47
CA12 O43570 4/20 0.47
CA7 P43166 3/20 0.47
CA14 Q9ULX7 3/20 0.47
CA3 P07451 2/20 0.47
CA4 P22748 2/20 0.47
CA6 P23280 2/20 0.47
CA5A P35218 2/20 0.47
CA5B Q9Y2D0 2/20 0.47
PLA2G2C Q5R387 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL345885 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL5015857 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL6061185 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL8085071 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL4193998 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL2194649 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL10731635 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL974536 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL10725263 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1
SCHEMBL3088278 1.00 RECQL (0.50) RECQLGLAHPGDTSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 701 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119804738-A Detection method for genotoxic impurities in dabigatran etexilate mesylate 核工业北京化工冶金研究院 2025-04-11 CN claimed
CN-113933400-B Detection method of genotoxic impurities in dabigatran etexilate bulk drug or preparation 石药集团恩必普药业有限公司 2024-01-12 CN claimed
CN-113933400-A Method for detecting genotoxic impurities in dabigatran etexilate bulk drug or preparation 石药集团恩必普药业有限公司 2022-01-14 CN claimed
CN-109942436-B Method for preparing N, N-dialkyl aniline compound by alkylation of alkyl p-toluenesulfonate 大连理工大学 2021-06-22 CN claimed
CN-110357889-A Protein degradation target compound, its antitumor application thereof, wherein mesosome and intermediate application 上海科技大学 2019-10-22 CN claimed
CN-106632358-A Method for preparing lurasidone hydrochloride intermediate 北京万全德众医药生物技术有限公司 2017-05-10 CN claimed
WO-2008147472-A1 ETHERS OF BISANHYDROHEXITOLS NEW JERSEY INSTITUTE OF TECHNOLOGY (US) 2008-12-04 WO claimed
US-20080021209-A1 Ethers of bisanhydrohexitols NEW JERSEY INSTITUTE OF TECHNOLOGY (US) 2008-01-24 US claimed
EP-0588906-B2 PROCESSIBLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE AND CONDUCTIVE PRODUCTS FORMED THEREFROM DUPONT DISPLAYS INC (US) 2003-06-18 EP claimed
EP-0588906-B1 PROCESSIBLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE AND CONDUCTIVE PRODUCTS FORMED THEREFROM UNIAX CORP (US) 2000-08-02 EP claimed
EP-0588906-A4 PROCESSIBLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE AND CONDUCTIVE PRODUCTS FORMED THEREFROM UNIAX CORP (US) 1994-08-24 EP claimed
EP-0588906-A1 PROCESSIBLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE AND CONDUCTIVE PRODUCTS FORMED THEREFROM UNIAX CORPORATION (US) 1994-03-30 EP claimed
WO-1992022911-A1 PROCESSIBLE FORMS OF ELECTRICALLY CONDUCTIVE POLYANILINE AND CONDUCTIVE PRODUCTS FORMED THEREFROM UNIAX CORPORATION (US) 1992-12-23 WO claimed
US-12637540-B2 Resin produced by polycondensation, and resin composition MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 2026-05-26 US disclosed
WO-2026105863-A1 BIFUNCTIONAL COMPOUND AND METHOD FOR PRODUCING BIFUNCTIONAL COMPOUND 三菱瓦斯化学株式会社 2026-05-21 WO disclosed
WO-2026105862-A1 BIFUNCTIONAL COMPOUND, COMPOUND, METHOD FOR PRODUCING COMPOUND, AND METHOD FOR PRODUCING BIFUNCTIONAL COMPOUND 三菱瓦斯化学株式会社 2026-05-21 WO disclosed
US-4012397-A 2-Benzoyl-3-amino-pyridines DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) 1977-03-15 US disclosed
US-4004012-A 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones STERLING DRUG INC. (US) 1977-01-18 US disclosed
US-3969361-A 2-Benzoyl-3-amino-pyridines DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) 1976-07-13 US disclosed
US-3960890-A CONTROL OF ECTOPARASITES BAYER AKTIENGESELLSCHAFT (DT) 1976-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12637540-B2 Resin produced by polycondensation, and resin composition TAF1, TAF5, PUF60 RECQL 3195/4885GLA 2317/4885HPGD 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.